Asia Pacific Left Ventricular Assist Device Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – Type of Flow (Pulsatile Flow and Non-Pulsatile Flow), Design (Implantable Ventricular Assist Devices and Transcutaneous Ventricular Assist Device

Asia Pacific Left Ventricular Assist Device Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – Type of Flow (Pulsatile Flow and Non-Pulsatile Flow), Design (Implantable Ventricular Assist Devices and Transcutaneous Ventricular Assist Devices), and Application (Bridge to Transplantation, Destination Therapy, Bridge to Recovery, and Bridge to Candidacy)

The Asia Pacific left ventricular assist device market is expected to grow from US$ 263.01 million in 2022 to US$ 370.99 million by 2028. It is estimated to register a CAGR of 5.9% from 2022 to 2028.

Untapped Potential in Emerging Economies to Drive Asia Pacific Left Ventricular Assist Device Market Growth in Coming Years

Emerging countries such as India and China are expected to offer significant growth opportunities to the left ventricular assist device market players mainly due to the rising patient population, increasing R&D activities, growing CVD awareness, surging disposable incomes, improving healthcare infrastructure, and comparatively lenient policies compared to developed countries. These emerging markets have also seen a sustained increase in heart failure cases over the past decade. To capitalize on high growth opportunities prevailing in emerging markets, manufacturers are adopting strategic activities such as R&D for business expansion in these countries. According to the World Bank, health spending in China and India, increased by 5.35% and 3.01%, respectively, from 2018 to 2019. According to the India Brand Equity Foundation, the healthcare sector in India has flourished at a CAGR of 17%; it was worth US$ 280 billion in 2020, with hospitals accounting for ~71% of revenue. In China, the number of private hospitals has doubled to reach 16,900 during 2011–2017. Private hospitals account for ~57.2% of total hospitals in the country. Therefore, advancements in healthcare facilities in developing economies, along with a surge in the number of hospitals, are likely to drive the adoption of LVADs in emerging economies in the Asia Pacific left ventricular assist device market.

Asia Pacific Left Ventricular Assist Device Market Overview

The Asia Pacific left ventricular assist device market is segmented into China, Japan, India, South Korea, Australia, South Korea, and the Rest of Asia Pacific. The market growth in this region is attributed to the rising geriatric population, increasing heart failure cases, surging cardiovascular disease prevalence, and inclusion of LVAD-associated costs in insurance coverage. Rapid socioeconomic progress and changes in China are affecting the lifestyle of populations, which in turn, increases the risk of cardiovascular diseases. According to an article published in BioMed Central (BMC), CVDs contribute to more than 40% of deaths in China. In addition, in 2019, ~120.33 million people suffered from CVDs in China. CVD further leads to heart failure; therefore, the increase in cases of CVDs fuels the demand for LVADs in China.

Asia Pacific Left Ventricular Assist Device Market Revenue and Forecast to 2028 (US$ Million)

Asia Pacific Left Ventricular Assist Device Market Segmentation

The Asia Pacific left ventricular assist device market is segmented into type of flow, design, application, and country.

Based on type of flow, the Asia Pacific left ventricular assist device market is segmented into non-pulsatile and pulsatile flow . The non-pulsatile segment registered the largest market share in 2022.

Based on design, the Asia Pacific left ventricular assist device market is bifurcated into implantable ventricular assist devices and transcutaneous ventricular assist devices . The implantable ventricular assist devices segment registered the largest market share in 2022.

Based on application, the Asia Pacific left ventricular assist device market is segmented into destination therapy, bridge to transplantation, bridge to candidacy, and bridge to recovery . The destination therapy segment registered the largest market share in 2022

The Asia Pacific left ventricular assist device market, based on country, is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the market in 2022.

ABIOMED Inc; Abbott Laboratories; Medtronic Plc; LivaNova Plc; Terumo Corp; BiVACOR Inc; Evaheart Inc; and BioVentrix Inc are the leading companies operating in the Asia Pacific left ventricular assist device market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Asia Pacific left ventricular assist device market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific left ventricular assist device market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the left ventricular assist device market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.